BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

Patent ExpiryPositive

AI Analysis

Summary

BioMarin Pharmaceutical announced a global patent settlement with Ascendis Pharma, resulting in a 5% share price increase. The specifics of the settlement terms and affected drug products are not detailed in the article.

Outcome Details

Global patent settlement agreement

Importance:6/10

Sentiment:

0.70

patent_settlementlegallitigation_resolution

Related Companies

$BMRN $ASND

Read the original article

Published by yahoo_finance on September 12, 2026 5:02 PM

Read Original